DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK MarketsDUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets

1 Day Clinical Trial Agreements Training Course: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets (Mar 18, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training Course (Mar 18, 2026)” training has been added to ResearchAndMarkets.com’s offering.

The life sciences sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. Having appropriate CTAs in place is therefore essential for managing relationships between the different stakeholders, and apportioning risk and responsibilities between them. If appropriate contractual arrangements are not in place, a clinical trial may not receive approval or issues may arise with the integrity or validity of the data collected. Further, disputes between the parties can arise if responsibilities are not clearly defined in the agreement.

This intensive short course provides essential insights into the legal framework governing clinical trials in the EU and UK, ensuring compliance, protecting intellectual property and managing liability risks.

The expert speakers will explain the dynamic and increasingly demanding regulatory and data protection landscape to better inform those negotiations and drafting these agreements.

Benefits of attending

By attending this seminar you will:

  • Learn about the regulatory framework concerning clinical trials in the EU and the UK
  • Understand the EU Clinical Trial Regulation and UK Human Use (Clinical Trials) (Amendment) Regulations 2024
  • Examine the roles and obligations of stakeholders including sponsors, CROs, investigators, and ethics committees
  • Navigate clinical trials approval, ethical approvals, policy issues, and the legal risks of non-compliance
  • Master informed consent, clinical trial transparency, and compensation models to mitigate legal exposure
  • Learn how to protect IP rights in clinical trials, draft strong confidentiality agreements, and manage publication clauses.

Who Should Attend:

This course has been specially designed for:

  • Lawyers and in-house legal teams
  • Contract managers
  • Clinical contract specialists
  • Clinical trial managers and professionals
  • R&D staff
  • Regulatory specialists
  • And CROs, sponsors and healthcare organisations looking to stay ahead in an evolving legal landscape.

Key Topics Covered:

Overview of the regulation of clinical trials – the legal framework governing clinical trials in the EU and the UK

  • What a clinical trial is and the types of clinical trials
  • Who the stakeholders are and their roles and obligations
  • EU regulatory framework under the Clinical Trial Regulation 536/2014/EU and the Clinical Trials Information System (CTIS)
  • UK framework post Brexit under the Human Use (Clinical Trials) (Amendment) Regulations 2024
  • Clinical trial approval, ethics approval and policy issues (eg Health Research Authority approval)
  • What could happen if a clinical trial is not conducted in accordance with the law

Consent, data and IP rights

Sponsors and CROs must meet obligations relating to transparency, participant consent and data protection in clinical trials. In turn, those obligations have an impact on parties’ liability risks and IP rights. This session will examine:

  • Participant consent and liability risks:
    • Transparency obligations and the publication of clinical trials outcomes
    • How transparency and consent interact with liability risks, including:
      • Compensation models
      • Clinical trials insurance
      • Product liability risks for licensed products
  • Data protection:
    • Overview of the requirements
    • Use of patient data during and after a clinical trial (particularly in light of the 3/2019 guidance from the European Data Protection Board)
  • Intellectual property rights:
    • Relevant IP rights associated with clinical trials
    • How to best protect any accruing IP rights
    • Drafting and negotiating of IP rights, confidentiality and publication clauses

Final questions

For more information about this training visit https://www.researchandmarkets.com/r/6n17d8

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
1 Logo
1 Price(1)
$0.008553
$0.008553$0.008553
+9.09%
USD
1 (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Hoskinson Says XRP and Cardano Projects Lead Tokenization Race

Hoskinson Says XRP and Cardano Projects Lead Tokenization Race

Cardano founder Charles Hoskinson says Web3-native platforms already operate at a scale traditional finance has yet to reach. Cardano founder Charles Hoskinson
Share
LiveBitcoinNews2025/12/27 07:59
Fed forecasts only one rate cut in 2026, a more conservative outlook than expected

Fed forecasts only one rate cut in 2026, a more conservative outlook than expected

The post Fed forecasts only one rate cut in 2026, a more conservative outlook than expected appeared on BitcoinEthereumNews.com. Federal Reserve Chairman Jerome Powell talks to reporters following the regular Federal Open Market Committee meetings at the Fed on July 30, 2025 in Washington, DC. Chip Somodevilla | Getty Images The Federal Reserve is projecting only one rate cut in 2026, fewer than expected, according to its median projection. The central bank’s so-called dot plot, which shows 19 individual members’ expectations anonymously, indicated a median estimate of 3.4% for the federal funds rate at the end of 2026. That compares to a median estimate of 3.6% for the end of this year following two expected cuts on top of Wednesday’s reduction. A single quarter-point reduction next year is significantly more conservative than current market pricing. Traders are currently pricing in at two to three more rate cuts next year, according to the CME Group’s FedWatch tool, updated shortly after the decision. The gauge uses prices on 30-day fed funds futures contracts to determine market-implied odds for rate moves. Here are the Fed’s latest targets from 19 FOMC members, both voters and nonvoters: Zoom In IconArrows pointing outwards The forecasts, however, showed a large difference of opinion with two voting members seeing as many as four cuts. Three officials penciled in three rate reductions next year. “Next year’s dot plot is a mosaic of different perspectives and is an accurate reflection of a confusing economic outlook, muddied by labor supply shifts, data measurement concerns, and government policy upheaval and uncertainty,” said Seema Shah, chief global strategist at Principal Asset Management. The central bank has two policy meetings left for the year, one in October and one in December. Economic projections from the Fed saw slightly faster economic growth in 2026 than was projected in June, while the outlook for inflation was updated modestly higher for next year. There’s a lot of uncertainty…
Share
BitcoinEthereumNews2025/09/18 02:59
Sharplink CEO: Stablecoins, RWA, and sovereign wealth funds will drive Ethereum's TVL to grow tenfold by 2026.

Sharplink CEO: Stablecoins, RWA, and sovereign wealth funds will drive Ethereum's TVL to grow tenfold by 2026.

PANews reported on December 27 that Sharplink CEO Joseph Chalom stated that the surge in stablecoins, tokenized RWAs, and the growing interest from sovereign wealth
Share
PANews2025/12/27 08:15